GlassScriptPhysician profile
Han Van Duong
NPI 1013070234
$11,494.45
in general payments reported to CMS, 2019-2025
31 companies · $1,492 in 2025
The $1,492 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,598 · 2020: $1,089 · 2021: $1,701 · 2022: $2,007 · 2023: $1,175 · 2024: $1,432 · 2025: $1,492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,099.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,890.46 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,201.68 | 2019-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,131.05 | 2019-2025 | Jardiance |
| Abbvie INC. | $842.28 | 2019-2022 | |
| Amgen INC. | $690.87 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $660.18 | 2022-2025 | |
| Gilead Sciences, INC. | $576.02 | 2019-2021 | |
| Lilly USA, LLC | $478.03 | 2019-2023 | Amyvid |
| Nestle Healthcare Nutrition INC. | $447.15 | 2020-2023 | |
| Amarin Pharma, INC. | $309.93 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $233.55 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $223.65 | 2019-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $205.34 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $199.42 | 2024-2025 | Zoryve |
| Glaxosmithkline, LLC. | $189.05 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $149.85 | 2024-2025 | |
| Mylan Specialty L.P. | $147.60 | 2019-2024 | Yupelri |
| Aimmune Therapeutics, INC. | $136.09 | 2024-2025 | Zenpep |
| Vivus LLC | $115.28 | 2022-2025 | Pancreaze |
| Sanofi-Aventis U.S. LLC | $107.88 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.61 | 2021-2023 | Xifaxan, Trulance |
| Dexcom, INC. | $99.20 | 2023 | Dexcom G7 Gss (161) |
| Abbott Laboratories | $78.52 | 2022 | |
| Radius Health, INC. | $57.25 | 2024-2025 | Tymlos |
| Allergan, INC. | $54.22 | 2019-2020 | |
| Agios Pharmaceuticals, INC. | $45.13 | 2025 | Pyrukynd |
| Almatica Pharma LLC | $30.43 | 2024 | Loreev Xr |
| Regeneron Healthcare Solutions, INC. | $27.19 | 2019 | |
| Shield Therapeutics INC | $26.74 | 2024 | |
| Ibsa Pharma INC. | $19.91 | 2025 | Flector, Licart, Tirosint |
| Eisai INC. | $16.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Han Duong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.